BUILDING IVDR-COMPLIANT PANELS FOR HAEMATOLOGICAL DISORDERS

DIAGNOSTIC PURPOSE OF THE IVDR CONJUGATED ANTIBODIES



The new IVDR (EU IVDR 2017/746) will ensure that IVD (in vitro diagnostics) products achieve the highest levels of safety and efficacy possible. Laboratory-developed tests (LDT)/in-house devices (IH-IVD), which constitute a majority of the clinical flow cytometry tests, will now be regulated by the new IVDR.

Under the new regulation, flow cytometry laboratories willing to build their own cocktail of conjugated antibodies for diagnostic purposes can use one of the following:

- Non-CE-marked monoclonal antibodies (mAb) Cocktail (RUO, and/or off-label use of CE-marked mAb) and bring their cocktail in compliance with IVDR or ensure all article 5.5 requirements are met, including among others, compliance with Annex I General Safety & Performances requirements, ISO15189 or other national provision related to accreditation, justify the absence of equivalent devices commercially available, plus adaptations to the QMS to make it appropriate for design and manufacture.

 OR
- A CE-marked mAb Cocktail in line with each mAb Instructions for Use (IFU) and intended purpose. The laboratories are not affected by the IVDR and might only have to perform either performance verification or validation, very similar to the current process.

ı		lecessit	ates t	.iiat aii	II mAbs	os ha	ve Int	ended	<u> </u>	ı			the application (<u></u>			T		
												Differential diagnosis of	Hematological disorders	Prognosis of patients having	Diagnosis of patients with	Monitor patients with known	transplantation	Diagnosis of in vitro	Differential diagnosis of	Monitor patients on allergen
			\ <u>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</u>									hematologically abnormal	(non-cancers included)	hematopoietic neoplasm/	suspected immunodeficiency	autoimmune disease	process or	activation of basophils	hematologically abnormal	specific immunotherar
		Pacific SNv2	rome	2 2				Ι,	,	APO	APO	patients.		hematological disorder	Monitor patients	or disorder	results	in response to allergens	patients suspected of	
)escription	Clone (Isotype species)	fic E	e O	SNV605	FITC	PE	ECD	PC5.5	PC7	C-A700 APC	C-A	Monitor patients with known			with known immunodeficiency			(allergic reactions)	having thrombocytopenic	
	(Isotype species)	* Blue 428	Orange	05				0		700	750	hematopoietic neoplasm							disorder.	
		- w	e																Monitor patients with known	
																			thrombocytopenic disorder	
CD1a	BL6 (IgG1 mouse)																			
	39C1.5 (IgG2a rat)									_										
	UCHT1 (IgG1 mouse) 13B8.2 (IgG1 mouse)	*		*																
	BL1a (IgG2a mouse)	*					Н			-										
	8H8.1 (IgG2a mouse)			*	k					-										
CD8	B9.11 (IgG1 mouse)			*	k															
	ALB1 (IgG1 mouse)	*		*																
	Bear1 (IgG1 mouse) BU15 (IgG1 mouse)																			
	SJ1D1 (IgG1 mouse)																			
CD13		*																		
CD14	RMO52 (IgG2a mouse)																			
	80H5 (IgM mouse)																			
	3G8 (IgG1 mouse)	*																		
	J3-119 (IgG1 mouse) B9E9 (IgG2a mouse)	*		*																
	SJ10.1H11 (IgG1 mouse)	*		*	k															
CD23	9P25 (IgG1 mouse)	*		*																
	ALB9 (IgG1 mouse)																			
	B1.49.9 (IgG2a mouse)	*		*																
	1A4CD27 (IgG1 mouse) D3HL60.251 (IgG1 mouse)	*																		
	581 (IgG1 mouse)	*																		
CD36	FA6.152 (IgG1 mouse)			*	k															
CD38	LS198-4-3 (IgG1 mouse)	*		*																
	T16 (IgG1 mouse)			₩																
	P2 (IgG1 mouse) DFT1 (IgG1 mouse)																			
	J33 (IgG1 mouse)																			
CD45RA	ALB11 (IgG1 mouse)																			
	2H4LDH11LDB9 (IgG1 mouse)																			
	UCHL1 (IgG2a mouse)																			
	JS11KSC2.3 (IgG1 mouse) N901 (IgG1 mouse)	*																		
	NC1 (IgM mouse)			*	k	Г														
CD59	P282E (IgG2a mouse)																			
CD61	SZ21 (IgG1 mouse)			*	k															
	CLB-Thromb/6 (IgG1 mouse)																			
	CLB-Gran/12 (IgG1 mouse) 22 (IgG1 mouse)																			
	88H7 (IgM mouse)																			
	TP1.55.3 (IgG2b mouse)																			
	YDJ1.2.2 (IgG1 mouse)	*		*																
	HM47 (IgG1 mouse)								+											
	CB3-1 (IgG1 mouse) 2G5 (IgG2a mouse)				k															
	TEA3/17.1.1 (IgG1 mouse)																			
	104D2D1 (IgG1 mouse)	*																		
	R34.34 (IgG1 mouse)																			
	B-A38 (IgG1 mouse)	*			k															
	OX-104 (IgG1 mouse) 97A6 (IgG1 mouse)	*		*																
	11E4B-7-6 (IgG1 mouse)																			
	FMC7 (IgM mouse)																			
	Immu-357 (IgG1 mouse)	*		*	k															
	Polyclonal (Goat)																			
	Polyclonal (Goat) CLB-MPO-1 (IgG2a mouse)																			
	7.1 (IgG1 mouse)																			
	IP26A (IgG1 mouse)																			
·	IMMU510 (IgG1 mouse)	*																		
	HT1 + HT4 + HT8 + HT9 (IgG mouse)																			
	UCHT1-FITC/13B8.2-PE (IgG1 mouse)																			
CD3/CD8	UCHT1-FITC/B9.11-PE (IgG1 mouse)																			
CD3/CD16+CD56	UCHT1-FITC/3G8+N901-PE (IgG1 mouse)																			
	UCHT1-FITC/J3-119-PE (IgG1 mouse)																			
	TOMOT TOWNS	1																		
.D3/CD19	UCHT1-FITC/Immu-357-PE (IgG1 mouse)																			

APC-A700: APC-Alexa Fluor[§] 700 APC-A750: APC-Alexa Fluor[§] 750

- * In development, pending achievement of CE compliance; not yet available for in vitro diagnostic use.
- § Alexa Fluor and Pacific Blue are registered trademarks of Molecular Probes, Inc.

BECKMAN COULTER Life Sciences

© 2023 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. For Beckman Coulter's worldwide office locations and phone numbers, please visit Contact Us at beckman.com/home